Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome

Clinical Oncology

Volumn 28, Issue 8, 2016, Pages 532-539

  Dueland, S ^a   Ree, A H ^b,c   Groholt K K ^a   Saelen, M G ^a   Folkvord, S ^a   Hole, K H ^a,c   Seierstad, T ^a   Larsen, S G ^a   Giercksky, K E ^a,c   Wiig, J N ^a   Boye, K ^a   Flatmark, K ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

5 fluorouracil; chemoradiotherapy; locally advanced rectal cancer; neoadjuvant chemotherapy; oxaliplatin

Indexed keywords

ALBUMIN; CAPECITABINE; CREATININE; ELECTROLYTE; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HAND FOOT SYNDROME; HEART ARREST; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; INFECTION; LONG TERM SURVIVAL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS SURGERY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION ENTEROPATHY; RADIATION SICKNESS; RECTUM CARCINOMA; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; VOMITING; ADVERSE EFFECTS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; RECTAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMORADIOTHERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84957899722     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.01.014     Document Type: Article

References (28)

1. [1] Aklilu, M., Eng, C., The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 8 (2011), 649–659.
2. [2] Bosset, J.F., Calais, G., Mineur, L., et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15 (2014), 184–190.
3. [3] Gerard, J.P., Azria, D., Gourgou-Bourgade, S., et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30 (2012), 4558–4565.
4. [4] Coleman, C.N., Lawrence, T.S., Kirsch, D.G., Enhancing the efficacy of radiation therapy: premises, promises, and practicality. J Clin Oncol 32 (2014), 2832–2835.
5. [5] McCarthy, K., Pearson, K., Fulton, R., et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev, 12, 2012, CD008368.
6. [6] Lawrence, T.S., Haffty, B.G., Harris, J.R., Milestones in the use of combined-modality radiation therapy and chemotherapy. J Clin Oncol 32 (2014), 1173–1179.
7. [7] Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008), 1007–1016.
8. [8] Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14 (2013), 1208–1215.
9. [9] Gerard, J.P., Azria, D., Gourgou-Bourgade, S., et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28 (2010), 1638–1644.
10. [10] Aschele, C., Cionini, L., Lonardi, S., et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29 (2011), 2773–2780.
11. [11] O'Connell, M.J., Colangelo, L.H., Beart, R.W., et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32 (2014), 1927–1934.
12. [12] Rodel, C., Liersch, T., Becker, H., et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13 (2012), 679–687.
13. [13] Rodel, C., Graeven, U., Fietkau, R., et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16 (2015), 979–989.
14. [14] Brown, G., Richards, C.J., Bourne, M.W., et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227 (2003), 371–377.
15. [15] Sorbye, H., Glimelius, B., Berglund, A., et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 22 (2004), 31–38.
16. [16] Braendengen, M., Tveit, K.M., Berglund, A., et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26 (2008), 3687–3694.
17. [17] MERCURY Study Group, Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Br Med J, 333, 2006, 779.
18. [18] Wittekind, C., Compton, C., Quirke, P., et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 115 (2009), 3483–3488.
19. [19] Bouzourene, H., Bosman, F.T., Seelentag, W., et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94 (2002), 1121–1130.
20. [20] Calvo, F.A., Serrano, F.J., Diaz-Gonzalez, J.A., et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol 17 (2006), 1103–1110.
21. [21] Chau, I., Brown, G., Cunningham, D., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24 (2006), 668–674.
22. [22] Koeberle, D., Burkhard, R., von Moos, R., et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98 (2008), 1204–1209.
23. [23] Gunnlaugsson, A., Nilsson, P., Kjellen, E., et al. The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay. Radiat Oncol, 4, 2009, 61.
24. [24] Chua, Y.J., Barbachano, Y., Cunningham, D., et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11 (2010), 241–248.
25. [25] Dewdney, A., Cunningham, D., Tabernero, J., et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30 (2012), 1620–1627.
26. [26] Schou, J.V., Larsen, F.O., Rasch, L., et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 23 (2012), 2627–2633.
27. [27] Al-Sukhni, E., Milot, L., Fruitman, M., et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 19 (2012), 2212–2223.
28. [28] Folkvord, S., Flatmark, K., Seierstad, T., et al. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?. Radiother Oncol 86 (2008), 428–434.